Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol | Zendy

Gregory G. Schwartz | Zendy; Philippe Gabríel Steg | Zendy; Deepak L. Bhatt | Zendy; Vera Bittner | Zendy; Rafael Díaz | Zendy; Shaun G. Goodman | Zendy; J. Wouter Jukema | Zendy; Yong-Un Kim | Zendy; Qian H Li | Zendy; Garen Manvelian | Zendy; Robert Pordy | Zendy; Timothée Sourdille | Zendy; Harvey D. White | Zendy; Michael Szarek | Zendy

Open Access

Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol

Author(s) -

Gregory G. Schwartz,

Philippe Gabríel Steg,

Deepak L. Bhatt,

Vera Bittner,

Rafael Díaz,

Shaun G. Goodman,

J. Wouter Jukema,

Yong-Un Kim,

Qian H Li,

Garen Manvelian,

Robert Pordy,

Timothée Sourdille,

Harvey D. White,

Michael Szarek

Publication year - 2021

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.120.049447

Subject(s) - alirocumab , medicine , acute coronary syndrome , mace , myocardial infarction , unstable angina , placebo , cardiology , statin , propensity score matching , hazard ratio , pcsk9 , cholesterol , lipoprotein , percutaneous coronary intervention , confidence interval , alternative medicine , ldl receptor , apolipoprotein a1 , pathology

Supplemental Digital Content is available in the text.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research